We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Stem Cell Therapeutics Announces Presentation of Modified REGENESIS Trial Results at the International Stroke Meeting
News

Stem Cell Therapeutics Announces Presentation of Modified REGENESIS Trial Results at the International Stroke Meeting

Stem Cell Therapeutics Announces Presentation of Modified REGENESIS Trial Results at the International Stroke Meeting
News

Stem Cell Therapeutics Announces Presentation of Modified REGENESIS Trial Results at the International Stroke Meeting

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stem Cell Therapeutics Announces Presentation of Modified REGENESIS Trial Results at the International Stroke Meeting"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stem Cell Therapeutics Corp. has announced that Dr. Steven Cramer of the University of California at Irvine will be presenting results from the REGENESIS-LED trial at the International Stroke Conference, in Los Angeles, California.

The title of the poster presentation is entitled, "Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS Trial)."

"This presentation represents an important opportunity to review and discuss the modified REGENESIS trial for the first time with the stroke community." said Dr. Allen Davidoff, Chief Scientific Officer of SCT. "SCT looks forward to discussions of this trial at the meeting and integrating those discussions into our ongoing strategic planning for the NTx®-265 program in Acute Ischemic Stroke".
Advertisement